Clinical trial NCT00153881: Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer
Official title: Docetaxel and Carboplatin Followed by a Dose-Ranging Study of Oral Capecitabine, Weekly Docetaxel, and Concomitant External Beam Radiotherapy for the Treatment of Patients With Stage II-III Carcinoma of the Esophagus and Gastro-Esophageal Junction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Esophageal Neoplasms
Keywords: Esophageal Cancer
Trimodality
Capecitabine
Xeloda
Gastro-esophageal Neoplasm
Carcinoma of the Esophagus
Lead sponsor: Dartmouth-Hitchcock Medical Center
Sponsor class: OTHER
Collaborators: name: Sanofi
name: Hoffmann-La Roche
First posted: 2005-09-12
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary objective is to determine the maximum tolerated dose of oral capecitabine, in combination with fixed doses of weekly docetaxel, and concurrent thoracic radiation for the treatment of patients with clinical stage II-III cancer of the esophagus and gastroesophageal junction.

Detailed description: This dose-ranging trial is designed to establish the phase II dose of capecitabine that can safely be given with docetaxel and radiation therapy for the treatment of patients with cancer of the esophagus and gastroesophageal junction. The docetaxel dose of 15 mg/m2/week, 5-fluorouracil dose of 200 mg/m2/week, and 50.4 Gy of thoracic radiation has been found to be the recommended doses from our initial phase I trial (DMS D9724). The Phase I study has been modified in an attempt to improve the pathological complete response rate by increasing the 5-fluorouracil exposure during thoracic radiation by replacing it with oral capecitabine. Capecitabine generates 5-fluorouracil selectively in tumor cells. This sequentially designed study of EUS staging, molecular analysis, neoadjuvant chemotherapy, concomitant chemotherapy and radiation, and surgical resection continues to expand our collaborative experience at Dartmouth Hitchcock in the treatment of cancer of the esophagus and gastroesophageal junction.

Eligibility criteria: Inclusion Criteria:

* Esophageal or gastroesophageal junction cancer that is locally advanced and surgically resectable (stage II or III disease).
* No prior therapy.
* Adequate organ function.

Exclusion Criteria:

* Evidence of metastasis (celiac axis lymph nodes are allowed).
* Cervical esophageal tumors.
* Peripheral or auditory neuropathy grade \>= 2.

Primary outcomes:
measure: To determine the maximum tolerated dose of oral capecitabine in combination with fixed doses of weekly docetaxel and concurrent radiation for the treatment of patients with clinical stage II-III cancer of the esophagus and gastroesophageal junction.
timeFrame: Enrollment of first subject to accural of last subject/ and data analysis
Secondary outcomes:
measure: To determine clinical and pathological response rate, rate of resectability, duration of response, and patterns of failure for patients with esophageal and gastroesophageal junction cancers.
timeFrame: Enrollment of first subject to accrual of last subject/ data analysis
measure: To determine the reliability of clinical staging and antitumor response rate assessment using endoscopic ultrasound.
timeFrame: Enrollment of first subject to accrual of last subject/ data analysis of study.
measure: To investigate the feasibility of assaying thymidine phosphorylase, cyclin B, MPM-2, and perturbations in cell cycle as potential markers of efficacy.
timeFrame: Enrollment of first subject to accrual of last/ data analysis of study.
Other outcomes:
Locations:
city: Lebanon
country: United States
facility: Norris Cotton Cancer Center
state: New Hampshire
Study officials:
affiliation: Norris Cotton Cancer Center
name: James R Rigas, MD
role: PRINCIPAL_INVESTIGATOR
References: